Growth with training wheels and a biotech lottery ticket duct taped to the side
Report created on Aug 5, 2026Risk profile
5/7
Diversification profile
3/5
Positions
-
SC Schwab U.S. Large-Cap Growth ETF
SCHG - US8085243009 38.00% -
SC Schwab U.S. Dividend Equity ETF
SCHD - US8085247976 34.00% -
SC Schwab U.S. Small-Cap ETF
SCHA - US8085246077 10.00% -
SC Schwab International Equity ETF
SCHF - US8085248057 8.50% -
SC Schwab Emerging Markets Equity ETF
SCHE - US8085247067 5.50% -
AR Arrowhead Pharmaceuticals Inc
ARWR - US04280A1007 2.50% -
PR ProQR Therapeutics BV
PRQR - NL0010872495 1.50%
This portfolio is basically a Schwab marketing brochure with two tiny biotech moonshots stapled on. Most of the weight is split between a large-cap growth fund and a dividend fund that partially cancel each other’s style, plus a sprinkle of small caps and a token nod to the rest of the world. Then come Arrowhead and ProQR, which are like tossing jalapeños into an otherwise mild stew. Structurally, it’s a barbell pretending to be diversified: boring core on one side, clinical-trial roulette on the other. The result is something that looks “moderately diversified” on paper but is still mostly one story: U.S. equities with a bit of style whiplash.
Growth
Historically, this thing has done well — $1,000 turning into $4,078 is nothing to sneer at. CAGR at 15.17% edges out the U.S. market and absolutely smokes the global benchmark. But it earned that win the hard way, with a -35.46% max drawdown in early 2020, slightly worse than the benchmarks. That’s the trade-off: you got paid a little extra for stomaching slightly deeper pain. CAGR (Compound Annual Growth Rate) is like your average speed over the whole trip; max drawdown is the part where the car went off the road. Past data is yesterday’s weather though — informative, not prophetic.
Projection
The Monte Carlo projections yank this portfolio back down to earth. Historically it behaved like a turbo-charged growth engine; forward simulations tone that down to an 8.08% annualized return and a median outcome of $2,788 over 15 years from $1,000. Monte Carlo is just a fancy way of saying “we threw this portfolio into a thousand alternate futures and averaged the mess.” The range is wide: from basically flat ($995 at the worst 5%) to heroic ($8,165 at the best 5%). Translation: the future is more boring than the backtest, with real odds of disappointment along with the upside.
Asset classes
- Stocks 100%
Asset-class “diversification” here is a trick question: it’s 100% stocks and 0% everything else. That’s like calling a pizza “well-rounded cuisine” because it has multiple toppings. Equities can absolutely drive long-term growth, but when markets crater, there’s nowhere to hide in this setup. No stabilizers, no shock absorbers, just full exposure to the stock market mood swings. Asset allocation is basically the volume knob on your risk; this one is turned firmly up. It’s coherent, but anyone calling it balanced has a creative relationship with the word “balanced.”
Sectors
- Technology 27%
- Health Care 17%
- Financials 11%
- Consumer Discretionary 9%
- Consumer Staples 9%
- Industrials 9%
- Telecommunications 8%
- Energy 6%
- Basic Materials 2%
- Real Estate 1%
- Utilities 1%
Sector-wise, the portfolio is clearly tech-curious and health-care-obsessed, with those two together eating up almost half the exposure. Financials, staples, and industrials get some love, but basic materials, real estate, and utilities are barely invited to the party. This is not a broad neutral slice of the global economy; it’s tilted toward growth-y, innovation-heavy areas that do amazingly well when optimism reigns and can look very fragile when sentiment flips. Sector concentration means the portfolio isn’t just betting on “stocks” — it’s betting on a certain style of economic winners continuing to win.
Regions
- North America 85%
- Europe Developed 6%
- Asia Emerging 3%
- Asia Developed 3%
- Japan 2%
- Africa/Middle East 1%
- Latin America 1%
- Australasia 1%
Geographically, the portfolio screams “America first and second and maybe third.” About 85% in North America, with the rest of the world getting table scraps: a few percent in developed Europe and Asia, single digits everywhere else. This is classic home bias — investing where it feels familiar, not necessarily where the opportunities are. The global economy is a lot larger and more diverse than this map suggests. When the U.S. leads, this looks smart; when other regions shine or the U.S. stumbles, this positioning turns from confidence into a very loud echo chamber.
Market capitalization
- Large-cap 41%
- Mega-cap 27%
- Mid-cap 18%
- Small-cap 9%
- Micro-cap 4%
The market-cap mix leans heavily on mega and large caps, together making up more than two-thirds of the portfolio. Mid caps are the side character, and small/micro caps are more like background extras. That means most of the risk and behavior comes from the big, widely owned giants, not from scrappy underfollowed names. It’s a very index-y profile with a token nod toward smaller companies. You get stability-ish from the giants with just enough small and micro-cap exposure to add some spice and volatility, but not enough to truly change the personality of the portfolio.
True holdings
-
AA Apple Inc. 4.04%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
NV NVIDIA Corporation 3.74%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
-
MS Microsoft Corporation 2.36%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
AM Amazon.com Inc 1.80%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
GO Alphabet Inc Class A 1.60%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
AB Abbott Laboratories 1.60%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
-
AM Amgen Inc 1.48%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
MR Merck & Company Inc 1.47%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
- Top 10 total 22.09%
The look-through holdings show the usual suspects hogging the stage: Apple, NVIDIA, Microsoft, Amazon, Alphabet — the standard “mega-cap tech starter kit.” They appear via multiple ETFs, so there’s hidden concentration baked in even if each fund looks diversified on its own. Then you’ve stapled on Arrowhead and ProQR directly, creating a weird barbell: super-mature mega caps on one side, speculative biotech on the other. And remember, coverage only sees ETF top-10s, so true overlap is probably higher under the surface. This portfolio is less diversified by company than the fund labels pretend.
Factors
Factor exposures are estimated using statistical models based on historical data and measure systematic (market-relative) tilts, not absolute portfolio characteristics. Results may vary depending on the analysis period, data availability, and currency of the underlying assets.
Factor-wise, the portfolio is hilariously normal. Everything sits around “neutral”: value, size, momentum, quality, yield, and low volatility are all basically market-like. Factor exposure is the ingredients list behind the shiny ETF labels — things like “cheap vs expensive,” “big vs small,” “steady vs wild.” Here, the mix is so middle-of-the-road it’s almost suspicious. For a portfolio with spicy biotech add-ons, the core factor profile is beige. The upside is no accidental extreme bets on any single style; the downside is you’re not really leaning into any coherent, deliberate factor story either.
Risk contribution
-
Schwab U.S. Large-Cap Growth ETF
Weight: 38.00% 42.2% -
Schwab U.S. Dividend Equity ETF
Weight: 34.00% 27.6% -
Schwab U.S. Small-Cap ETF
Weight: 10.00% 11.5% -
Schwab International Equity ETF
Weight: 8.50% 7.0% -
Arrowhead Pharmaceuticals Inc
Weight: 2.50% 4.9% - Top 5 risk contribution 93.3%
Risk contribution exposes who’s really driving the drama. The big growth ETF at 38% weight is pulling 42.23% of total risk — that’s expected. The small-cap ETF at 10% weight contributing 11.51% is also doing slightly more than its share. But the star of the chaos show is Arrowhead: a 2.5% position chucking in 4.9% of risk, almost double its proportional weight. That’s a tiny allocation punching like a mid-sized holding. Top three holdings crank out over 81% of portfolio risk, meaning a few positions are steering the ship while everyone else just decorates the cabin.
Risk vs. return
This chart shows the Efficient Frontier, calculated using your current assets with different allocation combinations. It highlights the best balance between risk and return based on historical data. "Efficient" portfolios maximize returns for a given risk or minimize risk for a given return. Portfolios below the curve are less efficient. This is informational and not a recommendation to buy or sell any assets.
Click on the colored dots to explore allocations.
On the efficient frontier, this portfolio is leaving performance on the table with all the grace of someone paying for premium gas in a Corolla. The Sharpe ratio at 0.68 is fine-ish, but it sits 1.52 percentage points below what could be achieved using the same ingredients with smarter weights. The optimal mix of these existing holdings could deliver higher return (26.3%) for higher risk and a much better Sharpe (0.97), while even the minimum variance version beats it on risk-adjusted terms. Translation: it’s not what you own that’s inefficient, it’s how you’ve put it together.
Ongoing product costs
- Schwab U.S. Small-Cap ETF 0.04%
- Schwab U.S. Dividend Equity ETF 0.06%
- Schwab Emerging Markets Equity ETF 0.11%
- Schwab International Equity ETF 0.06%
- Schwab U.S. Large-Cap Growth ETF 0.04%
- Weighted costs total (per year) 0.05%
Costs are the one area where this portfolio almost accidentally looks sophisticated. A total TER around 0.05% is impressively low — you’re basically paying index-fund pocket change for the whole setup. That’s like flying economy but getting upgraded snacks: no complaints there. The ETFs are all cheap workhorses, so at least the Schwab fan-club theme comes with a tangible benefit. When fees are this low, they’re not the villain in the story; if returns disappoint, it won’t be because of cost drag, it’ll be because of the actual bets baked into the portfolio.
What next?
Ready to invest in this portfolio?
Select a broker that fits your needs and watch for low fees to maximize your returns.
Create your own report?
Join our community!
The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.
Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.
Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.
Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.
By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.
Instrument logos provided by Elbstream.
Help us improve Insightfolio
Your feedback makes a difference! Share your thoughts in our quick survey. Take the survey